Keyphrases
Breast Cancer
100%
Cyclin-dependent Kinase 6 (CDK6)
100%
B-cell Lymphoma 2 (Bcl-2)
100%
Tumor Response
100%
Estrogen
100%
Dual Targeting
100%
ABT-199
83%
Palbociclib
66%
Cyclin-dependent Kinase 4/6 Inhibitors
66%
Combination Therapy
50%
Syngeneic
33%
Fulvestrant
33%
Mammary Tumor Models
33%
Patient-derived Xenograft
16%
Cell Cycle Arrest
16%
Apoptosis
16%
Patient-derived Organoids
16%
Venetoclax
16%
Bcl-2 Family
16%
Senescent Cells
16%
Cyclin
16%
Apoptotic Cell Death
16%
Functional Assay
16%
Immune System
16%
High Dose
16%
Acquired Resistance
16%
Endocrine Therapy
16%
Bcl-2 Inhibitor
16%
Breast Cancer Cell Lines
16%
Dephosphorylation
16%
Immunomodulatory Effect
16%
Single Therapy
16%
CRISPR-Cas9 Screen
16%
Senolysis
16%
Anti-PD-1 Therapy
16%
Triple Therapy
16%
Breast Cancer Relapse
16%
Doublet Therapy
16%
Medicine and Dentistry
Neoplasm
100%
Breast Cancer
100%
Cyclin-Dependent Kinase 4
100%
Cyclin-Dependent Kinase 6
100%
Palbociclib
80%
Combination Therapy
60%
Programmed Cell Death
40%
Tumor Model
40%
Breast Tumor
40%
Fulvestrant
40%
Clustered Regularly Interspaced Short Palindromic Repeat
20%
Organoid
20%
Cas9
20%
Cell Cycle Arrest
20%
Xenograft
20%
Cell Cycle Checkpoint
20%
Drug Megadose
20%
Immune System
20%
Hormone Therapy
20%
Cancer Recurrence
20%
Venetoclax
20%
Breast Cancer Cell Line
20%
Cyclin
20%
Dephosphorylation
20%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Breast Cancer
100%
Cyclin Dependent Kinase 4
100%
Cyclin Dependent Kinase 6
100%
Palbociclib
80%
Combination Therapy
60%
Tumor Model
40%
Breast Tumor
40%
Fulvestrant
40%
Venetoclax
20%
Cycline
20%
Endocrine Therapy
20%
Cancer Recurrence
20%